These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 18311357

  • 1. Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.
    Canestri A, Sow PS, Vray M, Ngom F, M'boup S, Kane CT, Delaporte E, Gueye M, Peytavin G, Girard PM, Landman R, ANRS 12-06/IMEA 012 Trial Study Group.
    MedGenMed; 2007 Oct 09; 9(4):7. PubMed ID: 18311357
    [Abstract] [Full Text] [Related]

  • 2. Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal.
    Canestri A, Sow PS, Vray M, Ngom F, M'boup S, Kane CT, Delaporte E, Gueye M, Peytavin G, Girard PM, Landman R, ANRS 12-06/IMEA 012 Trial Study Group.
    J Int AIDS Soc; 2007 Oct 09; 9(4):7. PubMed ID: 19825141
    [Abstract] [Full Text] [Related]

  • 3. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E, GESIDA 3903 Team.
    Clin Infect Dis; 2008 Oct 15; 47(8):1083-92. PubMed ID: 18781872
    [Abstract] [Full Text] [Related]

  • 4. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.
    Clin Ther; 1999 Nov 15; 21(11):1853-63. PubMed ID: 10890257
    [Abstract] [Full Text] [Related]

  • 5. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
    Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, van Leeuwen R, Weverling GJ, Kunanusont C, Lange JM, Cooper DA, Phanuphak P.
    AIDS; 2000 Jul 07; 14(10):1375-82. PubMed ID: 10930152
    [Abstract] [Full Text] [Related]

  • 6. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1601-10. PubMed ID: 10983647
    [Abstract] [Full Text] [Related]

  • 7. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D.
    J Infect Dis; 2010 Nov 15; 202(10):1529-37. PubMed ID: 20942650
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C.
    AIDS; 1999 Jul 30; 13(11):F87-93. PubMed ID: 10449279
    [Abstract] [Full Text] [Related]

  • 10. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
    Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P, HIV-NAT 002 and HIV-NAT 003 Study Team.
    J Acquir Immune Defic Syndr; 2004 Jun 01; 36(2):693-701. PubMed ID: 15167288
    [Abstract] [Full Text] [Related]

  • 11. Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.
    Swindells S, Cohen CJ, Berger DS, Tashima KT, Liao Q, Pobiner BF, Snidow JW, Pakes GE, Hernandez JE, NZTA4008 Study Team.
    BMC Infect Dis; 2005 Apr 08; 5():23. PubMed ID: 15819974
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
    Sánchez-Conde M, Palacios R, Sanz J, Rodríguez-Novoa S, Rivas P, Santos J, Sola J, Asensi V, de Mendoza C, Estrada V, Barreiro P, González-Lahoz J, Jiménez-Nacher I, Soriano V.
    AIDS Res Hum Retroviruses; 2007 Oct 08; 23(10):1237-41. PubMed ID: 17961110
    [Abstract] [Full Text] [Related]

  • 13. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.
    AIDS; 1999 Dec 03; 13(17):2377-88. PubMed ID: 10597779
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
    Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, Yogev R, McKinney RE, Abrams EJ, Mofenson LM.
    Pediatrics; 1999 May 03; 103(5):e62. PubMed ID: 10224206
    [Abstract] [Full Text] [Related]

  • 15. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA.
    AIDS; 2000 Jun 16; 14(9):1171-80. PubMed ID: 10894281
    [Abstract] [Full Text] [Related]

  • 16. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Laurent C, Tchatchueng Mbougua JB, Ngom Guèye NF, Etard JF, Diouf A, Landman R, Molinari N, Girard PM, Sow PS, Ndoye I, Delaporte E, ANRS 1215/1290 Study Group.
    Trop Med Int Health; 2011 Feb 16; 16(2):217-22. PubMed ID: 21087377
    [Abstract] [Full Text] [Related]

  • 17. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D, OzCombo 2 investigators.
    HIV Clin Trials; 2002 Feb 16; 3(3):177-85. PubMed ID: 12032876
    [Abstract] [Full Text] [Related]

  • 18. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
    Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD.
    AIDS; 2003 Sep 26; 17(14):2045-52. PubMed ID: 14502007
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.